Medical Management of Hyperthyroidism
First-Line Antithyroid Drug Selection
Methimazole is the preferred first-line antithyroid drug for most adults with hyperthyroidism because it can be administered as a single daily dose, has a longer half-life, causes fewer major side effects at therapeutic doses, and is more cost-effective than propylthiouracil 1, 2.
When to Use Propylthiouracil Instead
Propylthiouracil should be selected in three specific clinical scenarios 3, 4, 1:
First trimester of pregnancy – Methimazole is associated with rare congenital malformations including aplasia cutis and choanal/esophageal atresia, making propylthiouracil the safer choice during organogenesis 3, 5. However, switch to methimazole for the second and third trimesters due to propylthiouracil's hepatotoxicity risk 3, 4.
Thyroid storm – Propylthiouracil blocks peripheral conversion of T4 to T3, providing an additional therapeutic mechanism beyond thyroid hormone synthesis inhibition 1.
Lactating women – Both drugs appear in breast milk, but propylthiouracil is traditionally preferred, though recent evidence suggests methimazole is also safe during breastfeeding 5.
Dosing Regimens
Methimazole Dosing
Start with 10–30 mg once daily as a single dose 5, 2. The ability to use once-daily dosing improves adherence and is a key advantage over propylthiouracil 1, 2.
Propylthiouracil Dosing
Start with 100–300 mg divided every 6 hours (three to four times daily) 5. The shorter half-life necessitates multiple daily doses 1.
Dose Adjustment Strategy
- Monitor thyroid function tests periodically during therapy 3, 4.
- A rising serum TSH indicates the need for a lower maintenance dose of antithyroid medication 3, 4.
- Continue treatment for 12–18 months when using antithyroid drugs as primary therapy with the goal of inducing long-term remission in Graves' disease 6.
Beta-Blocker Use
Beta-adrenergic blocking agents should be used to control hyperthyroid symptoms (tachycardia, tremor, anxiety) while awaiting the therapeutic effect of antithyroid drugs 3, 4.
Important Dose Adjustments
- Hyperthyroidism increases the clearance of beta-blockers with high extraction ratios 3, 4.
- Reduce the beta-blocker dose when the patient becomes euthyroid to avoid bradycardia and other adverse effects 3, 4.
Monitoring Requirements
Laboratory Monitoring
Check complete blood count with differential and liver function tests before starting therapy and at the first sign of illness 3, 4.
- Prothrombin time (PT/INR) should be monitored, especially before surgical procedures, because antithyroid drugs may cause hypoprothrombinemia 3, 4.
- Thyroid function tests (TSH, free T4) should be checked periodically to guide dose adjustments 3, 4.
Warning Signs Requiring Immediate Evaluation
Instruct patients to report immediately 3, 4:
- Sore throat, fever, or general malaise – may indicate agranulocytosis
- Jaundice, pruritus, right upper quadrant pain, dark urine, or light-colored stools – may indicate hepatotoxicity (especially with propylthiouracil) 4
- New rash, hematuria, decreased urine output, dyspnea, or hemoptysis – may indicate vasculitis 3, 4
Special Considerations for Pregnancy
First Trimester
Use propylthiouracil during the first trimester to avoid methimazole-associated congenital malformations 3, 5, 1.
Second and Third Trimesters
Switch to methimazole for the second and third trimesters because propylthiouracil carries a risk of severe maternal hepatotoxicity, including hepatic failure requiring liver transplantation or resulting in death 3, 4.
Dosing Principles in Pregnancy
- Use the lowest effective dose to maintain maternal thyroid function in the high-normal range, as both drugs cross the placenta and can cause fetal goiter and cretinism 3, 4.
- Thyroid dysfunction often diminishes as pregnancy progresses, allowing dose reduction or even discontinuation several weeks to months before delivery 3, 4.
- Untreated or inadequately treated Graves' disease in pregnancy increases the risk of maternal heart failure, spontaneous abortion, preterm birth, stillbirth, and fetal/neonatal hyperthyroidism 3, 4.
Drug Interactions
Anticoagulants
Antithyroid drugs may enhance the effect of oral anticoagulants (e.g., warfarin) by inhibiting vitamin K activity 3, 4. Monitor PT/INR more frequently, especially before surgical procedures 3, 4.
Digitalis Glycosides
Serum digitalis levels may increase when a hyperthyroid patient becomes euthyroid on a stable digitalis regimen 3, 4. A reduced dose of digitalis may be needed 3, 4.
Theophylline
Theophylline clearance may decrease when hyperthyroid patients become euthyroid 3, 4. A reduced theophylline dose may be required 3, 4.
Common Pitfalls and Caveats
Agranulocytosis Risk
- Exercise particular care in patients receiving other drugs known to cause agranulocytosis 3, 4.
- Obtain white blood cell and differential counts immediately if the patient develops fever, sore throat, or signs of infection 4.
Hepatotoxicity Risk with Propylthiouracil
- Postmarketing reports of severe liver injury, including hepatic failure requiring liver transplantation or resulting in death, have been reported in pediatric patients treated with propylthiouracil 4.
- Methimazole is the preferred choice for pediatric patients requiring antithyroid drug therapy 3.
- Monitor liver function closely, especially during the first six months of propylthiouracil therapy 4.
Vasculitis Risk
- Cases of vasculitis resulting in severe complications and death have occurred with both methimazole and propylthiouracil 3, 4.
- Instruct patients to report symptoms promptly (new rash, hematuria, decreased urine output, dyspnea, hemoptysis) 3, 4.
Carcinogenesis Concerns
- Long-term animal studies (>1 year) have demonstrated thyroid hyperplasia and carcinoma formation with propylthiouracil and methimazole 3, 4.
- These findings are associated with continuous thyroid suppression and are also seen with dietary iodine deficiency and other causes of chronic TSH elevation 4.
- The clinical significance in humans remains unclear 3.
Treatment Duration and Definitive Therapy
Primary Medical Therapy
Antithyroid drugs can be used as primary treatment for 12–18 months to induce long-term remission in Graves' disease 6.
Preparative Therapy
Antithyroid drugs can be used short-term (weeks to months) to render patients euthyroid before radioiodine ablation or thyroidectomy 5, 6.
Definitive Treatment Options
- Radioiodine ablation is the most widely used treatment in the United States and is well tolerated, with the main long-term sequela being hypothyroidism 6, 7.
- Surgery (subtotal or near-total thyroidectomy) has limited but specific roles, particularly for large goiters causing compressive symptoms or when radioiodine is refused 6.
- Antithyroid drugs will not cure hyperthyroidism associated with toxic nodular goiter, making radioiodine the treatment of choice for this condition 6.